Inogen (INGN) to Release Earnings on Thursday

Inogen (NASDAQ:INGN) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Inogen to announce earnings of ($0.17) per share and revenue of $95.2330 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%.The firm had revenue of $85.11 million for the quarter, compared to analysts’ expectations of $82.35 million. On average, analysts expect Inogen to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Inogen Stock Performance

Shares of INGN stock opened at $6.92 on Wednesday. Inogen has a 52-week low of $5.34 and a 52-week high of $9.13. The company has a 50-day simple moving average of $6.47 and a two-hundred day simple moving average of $6.38. The company has a market capitalization of $187.39 million, a price-to-earnings ratio of -7.60 and a beta of 1.55.

Insiders Place Their Bets

In related news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total transaction of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares in the company, valued at approximately $33,257.40. This represents a 68.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC grew its position in shares of Inogen by 30.1% during the 3rd quarter. Armistice Capital LLC now owns 864,000 shares of the medical technology company’s stock valued at $7,059,000 after acquiring an additional 200,000 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Inogen by 37.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 589,273 shares of the medical technology company’s stock worth $3,960,000 after purchasing an additional 160,960 shares during the period. AQR Capital Management LLC lifted its stake in Inogen by 30.1% in the first quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock valued at $4,022,000 after purchasing an additional 130,381 shares during the last quarter. Bank of America Corp DE lifted its stake in Inogen by 292.9% in the second quarter. Bank of America Corp DE now owns 171,526 shares of the medical technology company’s stock valued at $1,206,000 after purchasing an additional 127,869 shares during the last quarter. Finally, Moore Capital Management LP bought a new position in Inogen during the third quarter valued at $942,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

INGN has been the topic of a number of research analyst reports. Freedom Capital upgraded Inogen to a “strong-buy” rating in a research note on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Inogen presently has a consensus rating of “Moderate Buy”.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.